OptiBiotix Health plc has reported a rise in revenue and profits.

The AIM-quoted life sciences business develops products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes.

In the 2025 calendar year revenue was up 30% to £1.13m, with an 82% in gross profit to £603,000.

Operating costs – including selling, R&D and patent costs, but excluding non-cash shared based payments – were stable at £2.6m.